Paper31433752
Angiotensin Type 1 Receptor Blockers in Heart Failure.
Singh KD and 1 other. Curr Drug Targets, 2020. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. Angiotensin Type 1 Receptor Blockers in Heart Failure. Papers, record 31433752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31433752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiotensin II Type 1 Receptor Blockers | Major topic |
| Heart Failure | Major topic |
| Angiotensin-Converting Enzyme Inhibitors | |
| Humans | |
| Receptor, Angiotensin, Type 1 | |
| Renin-Angiotensin System | |
| Treatment Outcome |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 HL057470 | NHLBI NIH HHS | United States | R01HL057470 | PubMed and NIH | NIH RePORTER |
| R01 HL115964 | NHLBI NIH HHS | United States | R01HL115964 | PubMed and NIH | NIH RePORTER |
| R01 HL132351 | NHLBI NIH HHS | United States | R01HL132351 | PubMed and NIH | NIH RePORTER |
| R01 HL142091 | NHLBI NIH HHS | United States | R01HL142091 | PubMed and NIH | NIH RePORTER |
References78
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20428262 | Role of the angiotensin II receptor blocker valsartan in heart failure. | Exp Clin Cardiol | 2001 | https://conductscience.org/library/papers/20428262 | PubMed |
| 2 | 14610160 | Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. | N Engl J Med | 2003 | https://conductscience.org/library/papers/14610160 | PubMed |
| 3 | 21983097 | Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients. | Clin Chim Acta | 2012 | https://conductscience.org/library/papers/21983097 | PubMed |
| 4 | 17148616 | Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/17148616 | PubMed |
| 5 | 9781693 | Angiotensinogen cleavage by renin: importance of a structurally constrained N-terminus. | FEBS Lett | 1998 | https://conductscience.org/library/papers/9781693 | PubMed |
| 6 | 11376628 | Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. | Cardiovasc Res | 2001 | https://conductscience.org/library/papers/11376628 | PubMed |
| 7 | 21848583 | Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. | J Clin Pharm Ther | 2012 | https://conductscience.org/library/papers/21848583 | PubMed |
| 8 | 7828295 | Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. | Circulation | 1995 | https://conductscience.org/library/papers/7828295 | PubMed |
| 9 | 26657004 | Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure. | Hypertens Res | 2016 | https://conductscience.org/library/papers/26657004 | PubMed |
| 10 | 15492298 | Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. | Circulation | 2004 | https://conductscience.org/library/papers/15492298 | PubMed |
| 11 | 22119063 | Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. | Atherosclerosis | 2012 | https://conductscience.org/library/papers/22119063 | PubMed |
| 12 | 15370071 | Endothelial function and oxidative stress. | Endothelium | 2004 | https://conductscience.org/library/papers/15370071 | PubMed |
| 13 | 21983318 | Azilsartan: a newly approved angiotensin II receptor blocker. | Cardiol Rev | 2011 | https://conductscience.org/library/papers/21983318 | PubMed |
| 14 | 25637937 | Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. | Eur Heart J | 2015 | https://conductscience.org/library/papers/25637937 | PubMed |
| 15 | 30206479 | Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM. | Card Fail Rev | 2018 | https://conductscience.org/library/papers/30206479 | PubMed |
| 16 | 12788798 | Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. | Endocr Rev | 2003 | https://conductscience.org/library/papers/12788798 | PubMed |
| 17 | 27536242 | Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study. | Front Pharmacol | 2016 | https://conductscience.org/library/papers/27536242 | PubMed |
| 18 | 3280490 | Angiotensin converting enzyme inhibitors. Properties and side effects. | Hypertension | 1988 | https://conductscience.org/library/papers/3280490 | PubMed |
| 19 | 28194766 | Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. | Br J Pharmacol | 2017 | https://conductscience.org/library/papers/28194766 | PubMed |
| 20 | 24705437 | The new Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014): a giant undertaking. | Hypertens Res | 2014 | https://conductscience.org/library/papers/24705437 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41572764 | Geniposide Attenuates Post-Myocardial Infarction Cardiac Remodeling via Parkin-Dependent Suppression of Hyperactivated Mitophagy. | Curr Med Chem | 2026 | https://conductscience.org/library/papers/41572764 | PubMed |
| 41465213 | Angiotensin-Converting Enzyme Inhibitors to Prevent Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Scientific Speculation or an Opportunity to Improve Real Clinical Practice? | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465213 | PubMed |
| 41131867 | A Computational Journey Toward an Optimal Design for Metamaterial Epicardial Passive Sleeves. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/41131867 | PubMed |
| 41035141 | Letter to the Editor: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study. | Epidemiol Health | 2025 | https://conductscience.org/library/papers/41035141 | PubMed |
| 39097838 | Mathematical modeling for prediction of physicochemical characteristics of cardiovascular drugs via modified reverse degree topological indices. | Eur Phys J E Soft Matter | 2024 | https://conductscience.org/library/papers/39097838 | PubMed |
| 38590561 | Transcriptome and proteome analyses reveal that upregulation of GSTM2 by allisartan improves cardiac remodeling and dysfunction in hypertensive rats. | Exp Ther Med | 2024 | https://conductscience.org/library/papers/38590561 | PubMed |
| 38566963 | Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future. | Front Cardiovasc Med | 2024 | https://conductscience.org/library/papers/38566963 | PubMed |
| 37504538 | The Impacts of Animal-Based Diets in Cardiovascular Disease Development: A Cellular and Physiological Overview. | J Cardiovasc Dev Dis | 2023 | https://conductscience.org/library/papers/37504538 | PubMed |
| 37057101 | The history and mystery of sacubitril/valsartan: From clinical trial to the real world. | Front Cardiovasc Med | 2023 | https://conductscience.org/library/papers/37057101 | PubMed |
| 36534965 | Pathophysiology and pharmacology of G protein-coupled receptors in the heart. | Cardiovasc Res | 2023 | https://conductscience.org/library/papers/36534965 | PubMed |
| 36085147 | Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs. | Cell Discov | 2022 | https://conductscience.org/library/papers/36085147 | PubMed |
| 35318654 | Structural perspectives on the mechanism of signal activation, ligand selectivity and allosteric modulation in angiotensin receptors: IUPHAR Review 34. | Br J Pharmacol | 2022 | https://conductscience.org/library/papers/35318654 | PubMed |
| 35033178 | Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial. | Trials | 2022 | https://conductscience.org/library/papers/35033178 | PubMed |
| 34445477 | The Role of Mitochondria-Derived Peptides in Cardiovascular Diseases and Their Potential as Therapeutic Targets. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34445477 | PubMed |
| 34200402 | Exploiting Knowledge on Structure-Activity Relationships for Designing Peptidomimetics of Endogenous Peptides. | Biomedicines | 2021 | https://conductscience.org/library/papers/34200402 | PubMed |
| 33013358 | Endogenous CCN5 Participates in Angiotensin II/TGF-β1 Networking of Cardiac Fibrosis in High Angiotensin II-Induced Hypertensive Heart Failure. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33013358 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31433752
GET https://conductscience.org/api/papers/v1/31433752/references?page=2